Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-6250 in Mild Hepatic Impairment
NCT07850999Phase 1Not yet recruiting
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Oct 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABI-6250 in hepatitis D (HDV), sponsored by Assembly Biosciences, Inc. Primary endpoints: Maximum Observed Plasma Concentration, Apparent Terminal Elimination Half Life and 9 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ABI-6250
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT07850999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07850999.